VEXAS综合征的临床特征:一项系统综述
该系统综述遵循PRISMA指南检索五个数据库,纳入经基因确诊的VEXAS综合征病例,共分析来自32个国家33篇病例报告和21个病例系列的720例患者。皮肤受累最常见(81.8%,95%CI:78.8-84.5%),其次为全身症状(69.4%,95%CI:66.0-72.7%)和呼吸系统疾病(61.3%,95%CI:57.6-64.7%),骨髓增生异常综合征发生于35.8%(95%CI:32.3-39.4%)的患者。
要点
- 皮肤受累为VEXAS综合征最常见表现,占81.8%(95%CI:78.8-84.5%)。
- 呼吸系统受累和多种血管并发症为既往认识不足的表现。
- 心脏受累占7.6%、肾脏疾病占7.0%、中枢神经系统表现占7.8%。
核心结论
- 该系统综述提供了迄今最全面的VEXAS综合征特征描述,建立了各器官系统的稳健患病率估计,并识别出具有重要临床意义的罕见表现,这些发现将有助于早期诊断、指导监测策略并引导未来研究重点。
研究设计与样本
- 遵循PRISMA指南的系统综述,检索五个数据库,纳入报告经基因确诊VEXAS病例的研究,采用严格纳入标准以减少重复计数并最大化数据效用,患病率估计使用Wilson得分区间计算。
主要发现
- 共分析来自32个国家的33篇病例报告和21个病例系列的720例患者。
- 皮肤受累占81.8%(95%CI:78.8-84.5%),全身症状占69.4%(95%CI:66.0-72.7%),呼吸系统疾病占61.3%(95%CI:57.6-64.7%)。
- 关节受累占47.3%(95%CI:43.5-51.2%),眼部疾病占44.3%(95%CI:40.5-48.2%),静脉血栓栓塞占41.8%(95%CI:38.3-45.4%)。
- 骨髓增生异常综合征发生于35.8%(95%CI:32.3-39.4%)的患者。
- 罕见但具有临床意义的表现包括心脏受累(7.6%)、肾脏疾病(7.0%)和中枢神经系统表现(7.8%)。
关键数值与推荐
- 皮肤受累81.8%(95%CI:78.8-84.5%),全身症状69.4%(95%CI:66.0-72.7%),呼吸系统疾病61.3%(95%CI:57.6-64.7%)。
- 关节受累47.3%(95%CI:43.5-51.2%),眼部疾病44.3%(95%CI:40.5-48.2%),静脉血栓栓塞41.8%(95%CI:38.3-45.4%)。
- 骨髓增生异常综合征35.8%(95%CI:32.3-39.4%),心脏受累7.6%,肾脏疾病7.0%,中枢神经系统表现7.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To systematically characterize the complete phenotypic spectrum of VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome through comprehensive analysis of all published cases since its discovery in 2020. METHODS: We conducted a systematic review following PRISMA guidelines across five databases. Studies reporting genetically confirmed VEXAS cases were included. To minimize duplicate counting while maximizing data utility, we applied stringent inclusion criteria. Prevalence estimates were calculated using Wilson score intervals. Results were discussed, with secondary analysis focusing on rare manifestations of the disease, and clinical recommendations as appropriate. RESULTS: Analysis of 720 patients from 33 case reports and 21 case series across 32 countries revealed cutaneous involvement as the predominant manifestation (81.8%, 95% CI: 78.8-84.5%), followed by constitutional symptoms (69.4%, 95% CI: 66.0-72.7%) and respiratory disease (61.3%, 95% CI: 57.6-64.7%). Joint involvement (47.3%, 95% CI: 43.5-51.2%), ocular disease (44.3%, 95% CI: 40.5-48.2%) and venous thromboembolism (41.8%, 95% CI: 38.3-45.4%) were also common. Myelodysplastic syndrome occurred in 35.8% (95% CI: 32.3-39.4%) of patients. Previously under-recognized manifestations included significant respiratory involvement and a broad spectrum of vascular complications. Rare but clinically significant features included cardiac involvement (7.6%), renal disease (7.0%) and CNS manifestations (7.8%). CONCLUSION: This systematic review provides the most comprehensive characterization of VEXAS syndrome to date, establishing robust prevalence estimates across all organ systems and identifying rare manifestations with important clinical implications. These findings will facilitate earlier diagnosis, inform monitoring strategies and guide future research priorities.
引用
- Al-Hakim A, Goldberg S, Gaillard S, et al. Clinical features in VEXAS syndrome: a systematic review. Rheumatology (Oxford). 2025. PMID: 40570089. doi:10.1093/rheumatology/keaf293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。